NCT02053818View on ClinicalTrials.gov

Remifentanil/Sufentanil for CABG+/-AVR Evaluated by Recovery, Cognitive Function, Haemodynamics and Biochemical Markers.

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

June 30, 2015

Study Completion Date

August 31, 2015

Conditions
Ischaemic Heart DiseaseAortic Stenosis
Interventions
DRUG

Remifentanil

Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia

DRUG

Sufentanil

Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia

Trial Locations (1)

8200

Aarhus University Hospital, Aarhus N

All Listed Sponsors
lead

Aarhus University Hospital

OTHER

NCT02053818 - Remifentanil/Sufentanil for CABG+/-AVR Evaluated by Recovery, Cognitive Function, Haemodynamics and Biochemical Markers. | Biotech Hunter | Biotech Hunter